Aminoglutethimide

Overview

An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p454)

Indication

For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer	2025/04/22	NCT06938503	Phase 2	Not yet recruiting	Tianjin Medical University Cancer Institute and Hospital
Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer	2025/04/08	NCT06916975	Phase 2	Not yet recruiting	Jin Xu
Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma	2025/02/13	NCT06825546	Phase 2	Recruiting	Sir Run Run Shaw Hospital
Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer	2025/01/17	NCT06781086	Phase 2	Not yet recruiting	Biotech Pharmaceutical Co., Ltd.
Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer	2024/12/09	NCT06722911	Phase 2	Recruiting	Zhejiang Provincial People's Hospital
Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis	2024/05/08	NCT06405685	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital
Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study	2024/05/08	NCT06404840	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital
Beta-lactam Intermittent Versus Continuous Infusion and Combination Antibiotic Therapy in Sepsis	2023/01/12	NCT05681442	Phase 4	Recruiting	Assistance Publique - Hôpitaux de Paris
Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer	2023/01/10	NCT05679050	Phase 2	Recruiting	Tianjin Medical University Cancer Institute and Hospital
Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic Cancer	2022/08/01	NCT05481476	Phase 2	Recruiting	Sun Yat-sen University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

AI-Powered Research

Premium Access